title: New strategies in melanoma: entering the era of combinatorial therapy.
abstract: The treatment of metastatic melanoma has been revolutionized over the past decade as effective molecularly targeted therapies and immunotherapies entered the clinic. It is hoped that deeper insights into the characteristics of patients and tumors that are most responsive will allow more precise patient selection for these therapies while understanding mechanisms of resistance will facilitate the develop of rational combinations or next-generation agents aimed at novel targets.
authors.affiliation: Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
authors.forename: Ryan J
authors.initials: RJ
authors.lastname: Sullivan
authors.affiliation: Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts. kflaherty@partners.org.
authors.forename: Keith T
authors.initials: KT
authors.lastname: Flaherty
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000276:immunology / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D060908:CTLA-4 Antigen; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor